OKYO Pharma Expands Scientific Advisory Board with Key Ophthalmology Expert
OKYO sits 18% above its 52-week low of $1.375.
Summary
OKYO Pharma announced the appointment of Dr. Marta Sacchetti to its Scientific Advisory Board, bolstering its expertise in ocular inflammatory and degenerative diseases.
Key Events · Executive and Board Changes · OKYO
-
Scientific Advisory Board Expansion
OKYO Pharma announced the appointment of Marta Sacchetti, MD, PhD, to its Scientific Advisory Board (SAB).
-
Enhanced Expertise
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseases, particularly neuro-inflammatory corneal diseases.
-
Strategic Clinical Guidance
Her experience, including as Global Head of Clinical Development in Ophthalmology, will help shape the global clinical development strategy for Urcosimod, the company's lead candidate for neuropathic corneal pain.
Analysis · OKYO · Life Sciences
The appointment of Dr. Marta Sacchetti, an international expert in neuro-inflammatory corneal diseases, significantly strengthens OKYO Pharma's Scientific Advisory Board. Her expertise is directly relevant to the company's lead drug candidate, Urcosimod, which is in clinical development for neuropathic corneal pain. This addition is crucial for guiding global clinical development strategy and execution, enhancing the company's scientific credibility as it advances its pipeline.
At the time of this filing, OKYO was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.7M. The 52-week trading range was $1.38 to $3.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.